SOURCE: Kalorama Information

Kalorama Information

March 25, 2011 09:43 ET

Does a Decade Make a Difference in Molecular Diagnostics? Yes and No

NEW YORK, NY--(Marketwire - March 25, 2011) - Even in a fast-breaking industry such as molecular testing, a few entrenched competitors continue to dominate the market, according to healthcare research analyst Kalorama Information. The same companies who led over ten years ago still lead the market today, as reported in Kalorama's latest round-up of the market, "The World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not."  

"Major players in molecular diagnostics back in 2000 were Roche Diagnostics and GenProbe with 45% and 25% of the market respectively," notes Shara Rosen, R.T., M.B.A., the author of the study. "The remaining 30% of the market was held by other players including Abbott Diagnostics, Becton Dickinson, Chiron (now part of Siemens Healthcare), Organon Teknika (now part of bioMérieux) and Digene (now part of Qiagen). 

According to the report, the current leaders are Roche, Abbott, Gen-Probe, Qiagen, Becton Dickenson and Siemens; these companies hold over half of the market.

"Sound familiar?" said Rosen. "Amazingly, very little has changed, and yet a lot has changed." 

Despite the dominance of these giants, the report notes the industry is growing at double-digit rates in some categories, thus creating an opportunity for new entrants. Challenges remain, as genetic discoveries with possible test applications are frequent; However, developing these concepts into viable commercial products can only occur if test products demonstrate utility over current solutions and are commercialized properly. According to the report, complexity is also an issue; predicted growth of the market will depend on the development of more user-friendly tests to penetrate beyond today's market of highly-trained technologists.

"One of the most telling situations preventing molecular testing from really taking off is that it has remained in the realm of larger tertiary care institutions and reference labs," Rosen said.

Kalorama Information's study, "World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not," separates fast-growth areas of molecular diagnostics from those that are slower-paced. It also estimates the market and provides a realistic look at its current and future role in various market segments. In addition, the report discusses tests and technologies that are currently available and those in the pipeline, and reviews competitors in the market and their latest moves. For more information, please visit: http://www.kaloramainformation.com/redirect.asp?progid=81292&productid=2879023.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter (http://www.twitter.com/KaloramaInfo) and LinkedIn (http://www.linkedin.com/groups?gid=2177845&trk=hb_side_g).

Contact Information